Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373347 · ClinicalTrials.gov registry record
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
A clinical trial of Liver Cancer, sponsored by Stanford University.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT00373347: Recruiting study of Liver Cancer, sponsored by Stanford University.
NCT00373347 is a study of Liver Cancer that is actively recruiting participants, run by Stanford University. The registered enrollment target is 600 participants, above the 440-participant average among 78 other Liver Cancer trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00373347, a study of Liver Cancer, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Primary Outcome
Blood specimens collected through another protocol, Patients would have signed informed consent for that protocol, and agreed to have their blood specimens stored for future research such as this one.
Conditions Studied
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2004-11 |
| Est. Completion | 2025-12 |
What NCT00373347 shows while recruiting
NCT00373347 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 440-participant average among 78 other Liver Cancer trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00373347 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00373347 about?
NCT00373347 is a clinical study titled "Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma". The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
What is the current status of trial NCT00373347?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2004-11. Estimated completion is 2025-12.
What conditions does trial NCT00373347 study?
This clinical trial studies the following conditions: Liver Cancer.
Who is sponsoring clinical trial NCT00373347?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373347 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00373347's enrollment target sits among peer trials
600 9th of 78 higher than 70 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
Collection of Blood From Patients With Cancer
RECRUITING
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
RECRUITING · NA
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia